{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/f1b4c29f\"></iframe>","width":"100%","height":180,"duration":4120,"description":"In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36548927/ 4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:https://pubmed.ncbi.nlm.nih.gov/35803286/ 5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/35366963/ 6. Epcoritamab + R2 in high-risk follicular lymphoma:https://meetings.asco.org/abstracts-presentations/218265 7. Glofitamab in Mantle Cell Lymphoma:https://ashpublications.org/blood/article/140/Supplement%201/178/489039","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}